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HEPARIN-BINDING IGF-1 PROVIDES SUSTAINED DELIVERY
OF IGF-1 TO CARTILAGE IN VIVO
R. Miller1, A. Grodzinsky1, K. Cummings2, R.T. Lee2, P. Patwari2
1MIT, Cambridge, MA; 2Brigham and Women’s Hosp., Cambridge,
MA
Purpose: IGF-1 stimulates cartilage growth and repair but is not a
practical therapy due to its short half-life in vivo. We modiﬁed IGF-1
by adding a heparin-binding domain, creating HB-IGF-1. HB-IGF-
1 is retained in bovine cartilage tissue and promotes sustained
proteoglycan synthesis compared to IGF-1.
In the present study, we examined the mechanism of HB-IGF-1
retention in cartilage and tested whether HB-IGF-1 could provide
sustained in vivo delivery of IGF-1 to rat cartilage after intra-
articular injection.
Methods: Protein Production: Both HB-IGF-1 and control IGF-1
were expressed with Xpress and 6x-His tags in E. coli and puriﬁed
by Ni-NTA afﬁnity and reverse-phase chromatography.
Bovine Cartilage with Enzyme Treatment: Cartilage disks (3 mm
diam, 0.5 mm thick) from calf femoropatellar grooves were cultured
in serum-free medium with 500nM HB-IGF-1 or IGF-1 for 2 days.
At Day 2, disks were washed and treated with either no enzyme,
chondroitinase ABC (0.4U/mL), or heparitinase (0.036U/mL). At
Day 4, half of the chondroitinase-treated disks were treated
with heparitinase; all other disks were incubated in enzyme-free
medium. On Day 6, IGF remaining in the tissue was detected by
Western analysis.
CHO cell binding: Mutant CHO cells lacking heparan sulfate (strain
pgsD-677) and wildtype CHO (K1) cells were incubated in serum-
free medium with 100nM HB-IGF-1 or IGF-1 for 3 h, washed, and
analyzed by Western.
Biacore: Chondroitin sulfate (CS) and heparan sulfate (HS) were
biotinylated and bound to a streptavidin-coated Biacore chip. HB-
IGF-1 or IGF-1 was ﬂowed across the chip to determine the
maximum amount of IGF-1 bound (RUmax).
Intra-articular injection in rat: 10ug HB-IGF-1, 10ug IGF-1, or saline
alone was injected into the knee joints of 2-month-old male
Sprague-Dawley rats. After one day, joint tissues were harvested
and extracted. Portions of extracts with equal total protein were
analyzed by Western.
Results: HB-IGF-1 but not IGF-1 remained bound to bovine
cartilage explants after 6 days (Fig. 1, No Enzyme). Treatment with
chondroitinase ABC greatly decreased binding, while heparitinase
had no effect (Fig. 1, C’ase and H’ase). In addition, HB-IGF-
1 bound CHO cells lacking HS equally well as wild-type cells,
indicating that HS is not required for binding. Biacore analysis
showed that HB-IGF-1 bound to both HS and CS at 250-500nM,
although HS binding was stronger than CS binding (Fig. 2). Control
IGF-1 did not bind any of the GAGs at concentrations up to 1 uM.
One day after intra-articular injection, HB-IGF-1 was retained in
rat knee articular cartilage, whereas IGF-1 was undetectable (Fig.
3, Articular Cartilage). HB-IGF-1 was detectable despite stronger
immunoreactivity of IGF-1 (Fig. 3, Protein Standards). Neither
IGF-1 was detected in patellar tendon extracts (Fig. 3, Tendon),
consistent with better delivery to the CS-rich cartilage.
Figure 1
Figure 2
Figure 3
Conclusions: HB-IGF-1 is retained in rat knee cartilage longer
than IGF-1 after intra-articular injection. Surprisingly, although
HB-IGF-1 binds most strongly to heparan sulfate, the enhanced
retention of HB-IGF-1 in cells and cartilage appears primarily due
to binding of chondroitin sulfate, which is much more abundant
in cartilage than HS. HB-IGF-1 may be a new therapeutic for
sustained and relatively speciﬁc delivery of IGF-1 to cartilage.
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A SINGLE INTRA-ARTICULAR INJECTION OF INTERLEUKIN
1 RECEPTOR ANTAGONIST IS INSUFFICIENT TO RESTORE
GAIT DEFICIENCY RESULTING FROM INTERLEUKIN-1
MEDIATED CARTILAGE DESTRUCTION IN A RODENT
MODEL
K.D. Allen, S.B. Adams Jr., D. Latt, D.L. Nettles, L.A. Setton
Duke Univ., Durham, NC
Purpose: Interleukin-1 (IL1) plays a pivotal role in osteoarthritis
(OA), regulating inﬂammatory and catabolic processes. IL1 re-
ceptor antagonist (IL1Ra) can block IL1-induced inﬂammation in
rheumatoid arthritis, and intra-articular injection of IL1Ra has been
evaluated as an OA treatment. IL1-mediated joint inﬂammation and
destruction has been modeled in the rat through intra-articular in-
jection of rat dermal ﬁbroblasts modiﬁed to over-express human
IL1β. Here, we examine the efﬁcacy of a single intra-articular
IL1Ra injection in reversing pain and functional loss in this model.
Methods: Pre-treatment measures of mechanical sensitivity and
gait were determined for male Wistar rats (n=14, day=-2). Right
knee joints then received a 30 μL injection containing 12,500
rat dermal ﬁbroblasts modiﬁed to overexpress human IL1β (day=-
1). The following day, rats received either a 30 μL intra-articular
injection of IL1Ra (0.65 mg/mL) or saline (n=7, day=0). Gait was
quantiﬁed on post-treatment day 2 and 6 using high-speed video,
and mechanical withdrawal thresholds were measured on post-
treatment day 1, 3, and 5.
Results: Following injection of IL1β overexpressing cells, rats
locomoted with faster velocities and longer stride lengths on post-
treatment day 2 and 6 relative to pre-treatment data (p<0.001);
however, rats treated with IL1Ra selected slower velocities than
rats receiving saline (p=0.056). Rats receiving saline demonstrated
asymmetric gait on post-treatment day 2 and 6 with a delayed time
